Clinical Trials in Detroit

Showing 15281-15300 of 19,719 trials

Multiple Ascending Dose (MAD) Combination in Subjects With Multiple Myeloma

NCT00884546

To evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of BMS-833923 administered alone, in combination with lenalidomide plus dexamethasone, or in combination with bortezomib in subjects with relapsed or refractory multiple myeloma.

Advanced Cancer, Various, NOS

Bristol-Myers Squibb27 participantsStarted Jul 2009

Duarte, California, United States • La Jolla, California, United States • Los Angeles, California, United States +5 more locations

COMPLETED< 1 mile

JC Virus Antibody Study of Participants With Relapsing Forms of MS Receiving Treatment With Natalizumab

NCT01070836

The primary objective of this study is to demonstrate that the incidence of progressive multifocal Leukoencephalopathy (PML) in natalizumab-treated participants who do not have detectable antibodies to John Cunningham virus (JCV) (antibody negative) is lower than in participants who have detectable antibodies to JCV (antibody positive). The secondary objectives of this study are to: Estimate the incidence of PML in natalizumab-treated participants who are anti-JCV antibody negative and anti-JCV antibody positive, based on a meta-analysis of data obtained from this study and other data sources; Define the prevalence of anti-JCV antibody in relapsing multiple sclerosis (MS) participants receiving natalizumab within the TYSABRI Outreach: United Commitment to Health (TOUCH) Prescribing Program; Determine changes in anti-JCV antibody status over time.

Relapsing Multiple Sclerosis

Biogen35,895 participantsStarted Mar 2010

Birmingham, Alabama, United States • Birmingham, Alabama, United States • Cullman, Alabama, United States +475 more locations

Multiple Ascending Dose (MAD) Combination in Subjects With Multiple Myeloma

JC Virus Antibody Study of Participants With Relapsing Forms of MS Receiving Treatment With Natalizumab

Find Trials by Condition in Detroit

A Study of Lumacaftor in Combination With Ivacaftor in Cystic Fibrosis Subjects Aged 12 Years and Older Who Are Homozygous for the F508del-CFTR Mutation

A Non-Interventional Study in Rheumatoid Arthritis Patients Treated With Tocilizumab (RoActemra/Actemra)

JC-Virus (JCV) Antibody Program

Randomized, Double-Blind, Placebo Controlled Study of the Short Term Clinical Effects of Tolvaptan in Patients Hospitalized for Worsening Heart Failure With Challenging Volume Management

CryoValve SG Pulmonary Human Heart Valve Post Clearance Study

A Study of Capecitabine (Xeloda) and Bevacizumab as a First-line Therapy in Patients With Metastatic Colorectal Cancer

Multi-layer Insoles for a Patient-specific Approach to Shear and Pressure Reduction in Diabetes-related Foot Ulcer

ZACTIMA (an Anti-EGFR / Anti-VEGF Agent) Combined With Docetaxel Compared to Docetaxel in Non-small Cell Lung Cancer

Study to Evaluate PF-04965842 in Patients With Moderate to Severe Psoriasis

Pharmacokinetics, Efficacy, and Safety Study of RI-002 (IGIV) in Subjects With Primary Immunodeficiency Diseases (PIDD)

ZD6474 (ZACTIMA™) Phase III Study in EGFR Failures

Effect of Ambulatory Continuous Femoral Nerve Blocks on Readiness-for-Discharge Following Total Knee Replacement

Study Of Two Dosing Regimens Of PF-04937319 Compared To An Approved Agent (Sitagliptin) In Patients With Type 2 Diabetes

ASR-XL Metal-on-Metal 522 Post-Market Surveillance Study

Flurbiprofen Tape for Treatment of Chronic Low Back Pain

Study of Tolerant Kidney Transplant Recipients

Phase II Study to Determine Predictive Markers of Response to BMS-734016 (MDX-010)

A Study Evaluating Veliparib as a Single Agent or in Combination With Chemotherapy in Subjects With Solid Tumors